Published in Cell Rep on January 23, 2014
A Big Bang model of human colorectal tumor growth. Nat Genet (2015) 3.77
Pan-cancer analysis of the extent and consequences of intratumor heterogeneity. Nat Med (2015) 1.98
Applying evolutionary biology to address global challenges. Science (2014) 1.90
Subclonal diversification of primary breast cancer revealed by multiregion sequencing. Nat Med (2015) 1.74
Cancer genomics: one cell at a time. Genome Biol (2014) 1.70
Identifying and quantifying heterogeneity in high content analysis: application of heterogeneity indices to drug discovery. PLoS One (2014) 1.58
An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors. Sci Transl Med (2015) 1.44
Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity. Nature (2017) 1.42
Cancer evolution: mathematical models and computational inference. Syst Biol (2014) 1.36
The first five years of single-cell cancer genomics and beyond. Genome Res (2015) 1.27
Identification of neutral tumor evolution across cancer types. Nat Genet (2016) 1.25
BitPhylogeny: a probabilistic framework for reconstructing intra-tumor phylogenies. Genome Biol (2015) 1.22
JARID1B is a luminal lineage-driving oncogene in breast cancer. Cancer Cell (2014) 1.19
Tumor evolution in response to chemotherapy: phenotype versus genotype. Cell Rep (2014) 1.17
Breast cancer intra-tumor heterogeneity. Breast Cancer Res (2014) 1.16
The dynamic control of signal transduction networks in cancer cells. Nat Rev Cancer (2015) 1.09
Punctuated copy number evolution and clonal stasis in triple-negative breast cancer. Nat Genet (2016) 1.01
Cancer systems biology: embracing complexity to develop better anticancer therapeutic strategies. Oncogene (2014) 1.00
Intra-tumor heterogeneity of cancer cells and its implications for cancer treatment. Acta Pharmacol Sin (2015) 0.99
Algorithms to model single gene, single chromosome, and whole genome copy number changes jointly in tumor phylogenetics. PLoS Comput Biol (2014) 0.98
In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer. Nat Genet (2015) 0.95
Molecular characterization and targeted therapeutic approaches in breast cancer. Breast Cancer Res (2015) 0.93
Intratumoral heterogeneity in a Trp53-null mouse model of human breast cancer. Cancer Discov (2015) 0.93
Optical metabolic imaging quantifies heterogeneous cell populations. Biomed Opt Express (2015) 0.93
The biology of circulating tumor cells. Oncogene (2015) 0.90
Higher gene expression variability in the more aggressive subtype of chronic lymphocytic leukemia. Genome Med (2015) 0.89
Interrogating open issues in cancer precision medicine with patient-derived xenografts. Nat Rev Cancer (2017) 0.87
Cancer: Clonal cooperation. Nature (2014) 0.86
Imaging tumour cell heterogeneity following cell transplantation into optically clear immune-deficient zebrafish. Nat Commun (2016) 0.85
GoIFISH: a system for the quantification of single cell heterogeneity from IFISH images. Genome Biol (2014) 0.85
Understanding tissue context influences on intratumour heterogeneity. Nat Cell Biol (2014) 0.84
Cancer stem cell related markers of radioresistance in head and neck squamous cell carcinoma. Oncotarget (2015) 0.82
Challenges in the management of advanced, ER-positive, HER2-negative breast cancer. Nat Rev Clin Oncol (2015) 0.81
Self-digitization microfluidic chip for absolute quantification of mRNA in single cells. Anal Chem (2014) 0.80
Genomic profiling of breast cancers. Curr Opin Obstet Gynecol (2015) 0.80
Intra-tumor heterogeneity from a cancer stem cell perspective. Mol Cancer (2017) 0.80
A journey to uncharted territory: new technical frontiers in studying tumor-stromal cell interactions. Integr Biol (Camb) (2015) 0.79
Spatial niche formation but not malignant progression is a driving force for intratumoural heterogeneity. Nat Commun (2016) 0.79
Translating neoadjuvant therapy into survival benefits: one size does not fit all. Nat Rev Clin Oncol (2016) 0.78
Classical pathology and mutational load of breast cancer - integration of two worlds. J Pathol Clin Res (2015) 0.78
An Emerging Allee Effect Is Critical for Tumor Initiation and Persistence. PLoS Comput Biol (2015) 0.78
Differential expression of neurogenes among breast cancer subtypes identifies high risk patients. Oncotarget (2016) 0.78
Cathepsin K induces platelet dysfunction and affects cell signaling in breast cancer - molecularly distinct behavior of cathepsin K in breast cancer. BMC Cancer (2016) 0.78
Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapy. Nat Commun (2016) 0.78
Molecular portraits: the evolution of the concept of transcriptome-based cancer signatures. Brief Bioinform (2015) 0.77
The shock of being united and symphiliosis. Another lesson from plants? Cell Cycle (2014) 0.77
Evaluation and consequences of heterogeneity in the circulating tumor cell compartment. Oncotarget (2016) 0.77
Turning the headlights on novel cancer biomarkers: Inspection of mechanics underlying intratumor heterogeneity. Mol Aspects Med (2015) 0.77
Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer. Oncologist (2016) 0.77
Classifying the Progression of Ductal Carcinoma from Single-Cell Sampled Data via Integer Linear Programming: A Case Study. IEEE/ACM Trans Comput Biol Bioinform (2015) 0.77
Statistical measures of transcriptional diversity capture genomic heterogeneity of cancer. BMC Genomics (2014) 0.77
Tumor Evolution: Linear, Branching, Neutral or Punctuated? Biochim Biophys Acta (2017) 0.77
A population genetics perspective on the determinants of intra-tumor heterogeneity. Biochim Biophys Acta (2017) 0.76
Novel hybrid phenotype revealed in Small Cell Lung Cancer by a transcription factor network model that can explain tumor heterogeneity. Cancer Res (2016) 0.76
Using Pharmacogenomic Databases for Discovering Patient-Target Genes and Small Molecule Candidates to Cancer Therapy. Front Pharmacol (2016) 0.76
How to be good at being bad: centrosome amplification and mitotic propensity drive intratumoral heterogeneity. Cancer Metastasis Rev (2015) 0.76
Computational Cancer Biology: An Evolutionary Perspective. PLoS Comput Biol (2016) 0.76
A comparative analysis of whole genome sequencing of oesophageal adenocarcinoma pre- and post-chemotherapy. Genome Res (2017) 0.76
FUNCTIONAL SUBCLONE PROFILING FOR PREDICTION OF TREATMENT-INDUCED INTRA-TUMOR POPULATION SHIFTS AND DISCOVERY OF RATIONAL DRUG COMBINATIONS IN HUMAN GLIOBLASTOMA. Clin Cancer Res (2016) 0.75
Stability-driven nonnegative matrix factorization to interpret spatial gene expression and build local gene networks. Proc Natl Acad Sci U S A (2016) 0.75
FISHtrees 3.0: Tumor Phylogenetics Using a Ploidy Probe. PLoS One (2016) 0.75
The evolution of tumour phylogenetics: principles and practice. Nat Rev Genet (2017) 0.75
Pointwise mutual information quantifies intratumor heterogeneity in tissue sections labeled with multiple fluorescent biomarkers. J Pathol Inform (2016) 0.75
Measuring intratumor heterogeneity by network entropy using RNA-seq data. Sci Rep (2016) 0.75
Why one-size-fits-all vaso-modulatory interventions fail to control glioma invasion: in silico insights. Sci Rep (2016) 0.75
Reduced genomic tumor heterogeneity after neoadjuvant chemotherapy is related to favorable outcome in patients with esophageal adenocarcinoma. Oncotarget (2016) 0.75
Tumour heterogeneity: the cancer kaleidoscope. Nat Rev Cancer (2014) 0.75
Initiation of aberrant DNA methylation patterns and heterogeneity in precancerous lesions of human hepatocellular cancer. Epigenetics (2017) 0.75
Combined bacterial and viral treatment: a novel anticancer strategy. Cent Eur J Immunol (2015) 0.75
Spatial Proximity to Fibroblasts Impacts Molecular Features and Therapeutic Sensitivity of Breast Cancer Cells Influencing Clinical Outcomes. Cancer Res (2016) 0.75
Quantification of HER2 and estrogen receptor heterogeneity in breast cancer by single-molecule RNA fluorescence in situ hybridization. Oncotarget (2017) 0.75
Proceedings of the third international molecular pathological epidemiology (MPE) meeting. Cancer Causes Control (2017) 0.75
Addressing intra-tumoral heterogeneity and therapy resistance. Oncotarget (2016) 0.75
Host-Microbiome Interaction and Cancer: Potential Application in Precision Medicine. Front Physiol (2016) 0.75
Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition. Cancer Discov (2017) 0.75
Genome evolution in ductal carcinoma in situ: invasion of the clones. J Pathol (2016) 0.75
Biologically Relevant Heterogeneity: Metrics and Practical Insights. SLAS Discov (2017) 0.75
Regional Bias of Intratumoral Genetic Heterogeneity of Apoptosis-Related Genes BAX, APAF1, and FLASH in Colon Cancers with High Microsatellite Instability. Dig Dis Sci (2015) 0.75
Molecular portraits of human breast tumours. Nature (2000) 94.14
Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A (2003) 59.17
Comprehensive molecular portraits of human breast tumours. Nature (2012) 47.39
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med (2012) 44.56
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (2007) 32.68
Tumour evolution inferred by single-cell sequencing. Nature (2011) 19.13
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature (2010) 18.69
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature (2012) 14.33
The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med (2007) 13.39
Molecular definition of breast tumor heterogeneity. Cancer Cell (2007) 12.67
Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst (2008) 11.93
The landscape of cancer genes and mutational processes in breast cancer. Nature (2012) 11.24
A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell (2010) 11.20
Cancer as an evolutionary and ecological process. Nat Rev Cancer (2006) 9.33
Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol (1998) 9.32
Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol (2006) 7.24
Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer (2012) 6.82
Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet (2006) 6.71
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature (2008) 5.98
Tumor heterogeneity: causes and consequences. Biochim Biophys Acta (2009) 5.90
Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol (2010) 5.50
The CD44+/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res (2008) 4.63
Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. J Clin Invest (2010) 4.22
Intravital imaging of metastatic behavior through a mammary imaging window. Nat Methods (2008) 4.13
Tumor heterogeneity and the biology of cancer invasion and metastasis. Cancer Res (1978) 3.54
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol (2006) 3.52
Intratumor heterogeneity: seeing the wood for the trees. Sci Transl Med (2012) 3.38
Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer. Clin Cancer Res (2010) 3.19
Cell type-specific DNA methylation patterns in the human breast. Proc Natl Acad Sci U S A (2008) 2.99
Heterogeneity in breast cancer. J Clin Invest (2011) 2.86
Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. J Clin Oncol (2012) 2.85
Cellular heterogeneity and molecular evolution in cancer. Annu Rev Pathol (2012) 2.56
Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. Cancer Cell (2013) 2.43
Tumor heterogeneity: biological implications and therapeutic consequences. Cancer Metastasis Rev (1983) 1.96
Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer (2012) 1.91
Genetic heterogeneity and cancer drug resistance. Lancet Oncol (2012) 1.91
A comprehensive survey of clonal diversity measures in Barrett's esophagus as biomarkers of progression to esophageal adenocarcinoma. Cancer Prev Res (Phila) (2010) 1.89
Genome-wide functional synergy between amplified and mutated genes in human breast cancer. Cancer Res (2008) 1.82
Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas. J Pathol (2010) 1.79
Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection. J Pathol (2012) 1.78
Epithelial-mesenchymal transition, cancer stem cells and treatment resistance. Breast Cancer Res (2012) 1.68
Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer. Cancer Treat Rev (2010) 1.62
An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer. Br J Cancer (2011) 1.62
Clonal evolution in hematological malignancies and therapeutic implications. Leukemia (2013) 1.50
High intratumor genetic heterogeneity is related to worse outcome in patients with head and neck squamous cell carcinoma. Cancer (2013) 1.43
Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer. Breast Cancer Res (2006) 1.08
The cell kinetics of human mammary cancers. Cancer (1979) 0.88
Primary chemotherapy in locally advanced breast cancer (LABC): effects on tumour proliferative activity, bcl-2 expression and the relationship between tumour regression and biological markers. Eur J Cancer (1998) 0.88
Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer. Breast Cancer Res Treat (2012) 0.85
Age- and pregnancy-associated DNA methylation changes in mammary epithelial cells. Stem Cell Reports (2015) 0.86